The Patient brings new perspective

Share this article:
Wolters Kluwer is launching The Patient, a quarterly journal that will look at reimbursement issues from a patient perspective.

“We're trying to change the world from one that says ‘no' to medical innovation to one that says, ‘Well, what does the patient think?'” says editor John F. P. Bridges, PhD, of Johns Hopkins Bloomberg School of Public Health. Bridges says formularies, governments and others making decisions about drug access need to break out of the cost-effectiveness model as an exclusive means of determining the value of a medication. The title, intended to complement PharmacoEconomics, will launch in the fourth quarter.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...